Evidence map›Paper›PMID 39885196›Full record

ArticleNPJ vaccines2025

Identifying falsified COVID-19 vaccines by analysing vaccine vial label and excipient profiles using MALDI-ToF mass spectrometry.

Benediktus Yohan Arman, Rebecca Clarke, Tehmina Bharucha, Laura Gomez Fernandez, John Walsby-Tickle, Michael Deats, Sara Mosca, Qianqi Lin, Sneha Banerjee, Shrikrishna R Chunekar and 15 more

Abstract read
In one paragraph

Article in NPJ vaccines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Benediktus Yohan ArmanDepartment of Biochemistry, University of Oxford, OX1 3QU, Oxford, UK.ORCID http://orcid.org/0000-0003-2378-2386
Rebecca ClarkeDepartment of Chemistry, University of Oxford, OX1 3TA, Oxford, UK.ORCID http://orcid.org/0009-0006-5971-3015
Tehmina BharuchaDepartment of Biochemistry, University of Oxford, OX1 3QU, Oxford, UK.
Laura Gomez FernandezDepartment of Biochemistry, University of Oxford, OX1 3QU, Oxford, UK.
John Walsby-TickleDepartment of Chemistry, University of Oxford, OX1 3TA, Oxford, UK.ORCID http://orcid.org/0000-0002-1287-9580
Michael DeatsMedicine Quality Research Group, NDM Centre for Global Health Research, Nuffield Department of Medicine, University of Oxford, Oxford, OX3 7LG, UK.
Sara MoscaCentral Laser Facility, Research Complex at Harwell, STFC Rutherford Appleton Laboratory, UKRI, Harwell Campus, Oxford, OX11 0QX, UK.ORCID http://orcid.org/0000-0001-9479-5614
Qianqi LinCentral Laser Facility, Research Complex at Harwell, STFC Rutherford Appleton Laboratory, UKRI, Harwell Campus, Oxford, OX11 0QX, UK.ORCID http://orcid.org/0000-0001-7578-838X
Sneha BanerjeeCentral Laser Facility, Research Complex at Harwell, STFC Rutherford Appleton Laboratory, UKRI, Harwell Campus, Oxford, OX11 0QX, UK.
Shrikrishna R ChunekarSerum Institute of India Pvt. Ltd., 212/2, Hadapsar, Pune, 411028, India.
Kundan D PatilSerum Institute of India Pvt. Ltd., 212/2, Hadapsar, Pune, 411028, India.
Sunil GairolaSerum Institute of India Pvt. Ltd., 212/2, Hadapsar, Pune, 411028, India.
Susanna DunachieMahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, 10400, Thailand.ORCID http://orcid.org/0000-0001-5665-6293
Hamid A MerchantDepartment of Bioscience, School of Health, Sport and Bioscience, University of East London, Water Lane, London, E15 4LZ, UK.ORCID http://orcid.org/0000-0002-7668-5013
Robert StokesAgilent Technologies LDA UK, Becquerel Avenue, Didcot, OX11 0RA, UK.
Rutendo KuwanaRegulation and Safety Unit, Regulation and Prequalification Department, Access to Medicines and Health Products Division, World Health Organization (WHO), Geneva, Switzerland.
Alexandrine MaesRegulation and Safety Unit, Regulation and Prequalification Department, Access to Medicines and Health Products Division, World Health Organization (WHO), Geneva, Switzerland.ORCID http://orcid.org/0000-0002-7352-8282
Jean-Philippe CharrierDepartment of Microbiology Research & Development, bioMérieux, Marcy l'Étoile, France.
Fay ProbertDepartment of Chemistry, University of Oxford, OX1 3TA, Oxford, UK.
Céline CailletMedicine Quality Research Group, NDM Centre for Global Health Research, Nuffield Department of Medicine, University of Oxford, Oxford, OX3 7LG, UK.ORCID http://orcid.org/0000-0002-5554-2603
Pavel MatousekMedicine Quality Research Group, NDM Centre for Global Health Research, Nuffield Department of Medicine, University of Oxford, Oxford, OX3 7LG, UK.
James McCullaghDepartment of Chemistry, University of Oxford, OX1 3TA, Oxford, UK.ORCID http://orcid.org/0000-0003-4733-1205
Paul N NewtonMedicine Quality Research Group, NDM Centre for Global Health Research, Nuffield Department of Medicine, University of Oxford, Oxford, OX3 7LG, UK. paul.newton@ndm.ox.ac.uk.
Nicole ZitzmannDepartment of Biochemistry, University of Oxford, OX1 3QU, Oxford, UK.
Bevin GangadharanDepartment of Biochemistry, University of Oxford, OX1 3QU, Oxford, UK. bevin.gangadharan@bioch.ox.ac.uk.ORCID http://orcid.org/0000-0002-7466-2977

Funding

DH | National Institute for Health Research (NIHR) NIHR300791Wellcome Trust 222506Wellcome Trust (Wellcome) 222506/Z/21/ZWorld Health Organization 001
6 · The paper itself

Abstract

The rapid development and worldwide distribution of COVID-19 vaccines is a remarkable achievement of biomedical research and logistical implementation. However, these developments are associated with the risk of a surge of substandard and falsified (SF) vaccines, as illustrated by the 184 incidents with SF and diverted COVID-19 vaccines which have been reported during the pandemic in 48 countries, with a paucity of methods for their detection in supply chains. In this context, matrix-assisted laser desorption ionisation-time of flight (MALDI-ToF) mass spectrometry (MS) is globally available for fast and accurate analysis of bacteria in patient samples, offering a potentially accessible solution to identify SF vaccines. We analysed the COVISHIELD™ COVID-19 vaccine; falsified versions of which were found in India, Myanmar and Uganda. We demonstrate for the first time that analysis of spectra from the vaccine vial label and its adhesive could be used as a novel approach to detect falsified vaccines. Vials tested by this approach could be retained in the supply chain since it is non-invasive. We also assessed whether MALDI-ToF MS could be used to distinguish the COVISHIELD™ vaccine from surrogates of falsified vaccines and the effect of temperature on vaccine stability. Both polysorbate 80 and L-histidine excipients of the genuine vaccine could be detected by the presence of a unique combination of MALDI-ToF MS peaks which allowed us to distinguish between the genuine vaccines and falsified vaccine surrogates. Furthermore, even if a falsified product contained polysorbate 80 at the same concentration as used in the genuine vaccine, the characteristic spectral profile of polysorbate 80 used in genuine products is a reliable internal marker for vaccine authenticity. Our findings demonstrate that MALDI-ToF MS analysis of extracts from vial labels and the vaccine excipients themselves can be used independently to detect falsified vaccines. This approach has the potential to be integrated into the national regulatory standards and WHO's Prevent, Detect, and Respond strategy as a novel effective tool for detecting falsified vaccines.

Identifiers

PMID39885196
PMCPMC11782545

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.